Literature DB >> 4863134

Hemopoietic spleen colony studies. IV. Phytohemagglutinin and hemopoietic regeneration.

J L Curry, J J Trentin.   

Abstract

The effects of phytohemagglutinin (PHA) were studied in irradiated mice to see if a definite myeloproliferative effect could be demonstrated in vivo. The data obtained suggested the following conclusions. PHA treatment of the bone marrow donor only, causes a consistent but slight reduction in transplantable spleen colony-forming unit (CFU) content of the bone marrow 24 hr after the last PHA injection, but no change was found in the proportion of the various colony types. PHA treatment of the irradiated recipient of normal bone marrow causes no change in the number of spleen colonies. However, 8-day colonies are only about half normal size, are much more likely to be of mixed cell types, contain many large undifferentiated blastoid cells, but fewer transplantable CFU. The spleen sinusoids are packed with hemopoietic cells. Spleen colonies developing in hosts receiving daily injections of PHA show, in addition to the usual spectrum of cell types, a high proportion of unusual blastoid cells resembling the PHA transformed peripheral lymphocytes seen in vitro. The function of these cells is not known, but they may represent augmented proliferation and/or transformation of stem cells. PHA administered after irradiation significantly increased the number of endogenous spleen colonies, and, at certain doses of irradiation, improved postirradiation survival. PHA administered before irradiation had no effect on the number of endogenous spleen colonies formed, or on postirradiation survival. On the basis of these and other data, possible modes of action of PHA are discussed.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4863134      PMCID: PMC2138396          DOI: 10.1084/jem.126.5.819

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Purification and properties of the phytohemagglutinin of Phaseolus vulgaris.

Authors:  D A RIGAS; E E OSGOOD
Journal:  J Biol Chem       Date:  1955-02       Impact factor: 5.157

2.  The human small lymphocyte: its possible pluripotential quality.

Authors:  K CARSTAIRS
Journal:  Lancet       Date:  1962-04-21       Impact factor: 79.321

3.  [Study on the role of phytohemagglutinin in man as a hematologic protector during massive anticancer chemotherapy].

Authors:  L Israel; J Delobel; E Bernard
Journal:  Pathol Biol       Date:  1965-10

4.  Production of clones of lymphoid cell populations.

Authors:  T Mekori; L Chieco-Bianci; M Feldman
Journal:  Nature       Date:  1965-04-24       Impact factor: 49.962

5.  Effect of phytohaemagglutinin on marrow regeneration in rodents.

Authors:  R J Papac
Journal:  Lancet       Date:  1966-01-08       Impact factor: 79.321

6.  On stem-cell recovery after irradiation.

Authors:  D D Porteous; L G Lajtha
Journal:  Br J Haematol       Date:  1966-03       Impact factor: 6.998

7.  Hemopoietic spleen colony studies. I. Growth and differentiation.

Authors:  J L Curry; J J Trentin
Journal:  Dev Biol       Date:  1967-05       Impact factor: 3.582

8.  Effects of phytohaemagglutinin in vitro on cells other than lymphocytes.

Authors:  H L Ioachim
Journal:  Nature       Date:  1966-05-28       Impact factor: 49.962

9.  Effect of phytohemagglutinin-M (PHA) on the spleen-colony-forming capacity of mouse lymph node and blood cells.

Authors:  H S Micklem
Journal:  Transplantation       Date:  1966-11       Impact factor: 4.939

10.  Hemopoietic spleen colony studies. II. Erythropoiesis.

Authors:  J L Curry; J J Trentin; N Wolf
Journal:  J Exp Med       Date:  1967-04-01       Impact factor: 14.307

View more
  2 in total

Review 1.  The development and involution of the lymphoid system and immunologic capacity.

Authors:  R A Good; J Finstad
Journal:  Trans Am Clin Climatol Assoc       Date:  1968

2.  Defects in hematopoietic differentiation in NZB and NZC mice.

Authors:  N L Warner; M A Moore
Journal:  J Exp Med       Date:  1971-08-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.